Gabapentin Conversations: Use, Misuse, Overdose, and Safe Prescribing
Tracking # 20-1352820
Course overview
Gabapentin is FDA-approved for postherpetic neuralgia in adults, for adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy. The dosage and frequency of dosing depend on the condition being treated, the patient's age, and other factors. It is not a federally controlled substance, but multiple states have enacted rules to monitor its use due to concerns. Currently, widespread off-label prescribing has led to inconsistent monitoring and limited awareness of formulation differences. Scientists are also questioning the efficacy and safety of gabapentin. This has resulted in variable state regulations regarding gabapentin. Enhanced clinical knowledge, which promotes safe prescribing, improves patient monitoring, prevents adverse outcomes, and supports regulatory compliance, is crucial for optimizing therapeutic benefits and minimizing risks.
Subject areas
This course counts toward the state boards and subject areas below.